Happy Diwali! Our team is celebrating the festival of lights. You can order and pay as usual; all orders ship from 16 November.

Free shipping on orders over $149
SafeRxPills - Online Pharmacy
These products are intended for personal use only. We are not licensed by the FDA.
Back to BlogMen's Health

Sildenafil 20 mg (Revatio): Uses, PAH Dose, Trial Results, Side Effects and Cost

L

Lokesh Maurya

Dr. James Peterson is a board-certified urologist specializing in men's sexual health. He has published numerous studies on erectile dysfunction treatments and PDE5 inhibitors.

March 24, 202621 min read
Last updated: October 20, 2026
Share:
In this article (23 sections)

A 20 mg sildenafil tablet is the strength made for pulmonary arterial hypertension (PAH), high blood pressure in the arteries of the lungs. In the United States it is sold as REVATIO and as generic sildenafil 20 mg, and in India under brand names such as Assurans and Cardiax. It contains the same active ingredient as Viagra, but it is a different product with a different dose, a different schedule and a different evidence base.

This guide sets out what the 20 mg tablet is approved for, how it is dosed in adults and children, what the trials behind it found, the side effects and warnings on its label, and what a 20 mg tablet costs US pharmacies. It also answers a question many people search for: why 20 mg tablets sometimes turn up in conversations about erectile dysfunction (ED). All label figures come from the current US REVATIO prescribing information (Viatris, effective December 2024) unless stated otherwise.

The short answer

Sildenafil 20 mg is approved to treat PAH (WHO Group I) in adults and in children aged 1 to 17. The usual adult dose is 20 mg three times a day, and the label allows titration up to 80 mg three times a day based on symptoms and tolerability. In the main trial, SUPER-1, all three doses tested (20, 40 and 80 mg three times a day) increased the distance walked in six minutes by 45 to 50 metres more than placebo, and the doses did not differ from each other on that measure. A later study in 385 adults found fewer cases of clinical worsening at 80 mg than at 5 mg three times a day, which is why higher doses remain allowed. Common side effects are headache, flushing, indigestion, diarrhoea, nosebleeds and limb or muscle pain. It must never be combined with nitrates or riociguat. A 20 mg tablet is not labelled for ED; using it for ED is off-label prescribing, a decision for a doctor, not something to work out at home.

What a 20 mg sildenafil tablet is

Sildenafil citrate is a phosphodiesterase type 5 (PDE5) inhibitor. The REVATIO label states plainly that sildenafil "is also marketed as VIAGRA for erectile dysfunction". The molecule is the same; the products are not interchangeable.

FeatureSildenafil 20 mg (REVATIO and generics)Sildenafil for ED (Viagra and generics)
Approved usePulmonary arterial hypertension, adults and children 1 to 17Erectile dysfunction in men
Tablet strengths on the US label20 mg (REVATIO tablet is white, round, engraved "RVT 20" and "VLE")25, 50 and 100 mg (Viagra is a blue rounded diamond)
Other formsOral suspension 10 mg/mL; injection 10 mg/12.5 mLTablet
Usual scheduleThree times a day, every dayAs needed, at most once a day
Usual adult dose20 mg three times a day50 mg about 1 hour before sex

Sources: REVATIO label sections 1, 2 and 3; Viagra US label (Viatris, revised 11/2023) sections 1, 2 and 3. If you want to know whether generic sildenafil matches the brand, that is covered in our guide to whether generic Viagra works as well as Viagra.

What sildenafil 20 mg is approved for

The US label gives two indications, both for PAH classed as World Health Organization (WHO) Group I:

  • Adults: to improve exercise ability and delay clinical worsening.
  • Children aged 1 to 17: to improve exercise ability and, in children too young for standard exercise testing, the lung blood flow measures thought to underlie that improvement. Safety and effectiveness have not been established under 1 year of age.

The label does not list any other use. Pulmonary hypertension from other causes, such as sickle cell disease, is not an approved use, and the label carries a specific warning about it (see the warnings section below).

What PAH means in the trials

In SUPER-1, the trial behind the adult approval, PAH was defined as a mean pulmonary artery pressure of 25 mmHg or more at rest, with a pulmonary capillary wedge pressure below 15 mmHg. These pressures are measured with a catheter passed into the heart, not a home blood pressure cuff; PACES-1, for example, required right heart catheterisation within 21 days before entry. Most patients were in WHO functional classes II and III, meaning symptoms such as breathlessness and tiredness with ordinary or less than ordinary activity.

That definition matters for readers. PAH is diagnosed and managed by specialists, and nobody should start a 20 mg tablet because they feel short of breath. Breathlessness has many causes, several of which need urgent care.

How it works in the lungs

PDE5 breaks down a chemical messenger called cyclic GMP in the smooth muscle of the lung arteries. By blocking PDE5, sildenafil lets cyclic GMP build up, the muscle relaxes and the lung blood vessels widen, with a smaller widening effect in the rest of the body (label section 12.1).

In SUPER-1, the label reports these average changes after 12 weeks on 20 mg three times a day, compared with placebo:

Measure at week 12Placebo (n = 65)Sildenafil 20 mg (n = 65)
Mean pulmonary artery pressure (mmHg)+0.6-2.1
Pulmonary vascular resistance (dyn·s/cm5)+49-122
Cardiac output (L/min)-0.1+0.4
Heart rate (beats/min)-1.3-3.7

Source: REVATIO label section 12.2, Table 2. The label notes that the link between these changes and the improvement in walking distance is unknown.

The usual dose and the maximum

For adults, the label sets out:

  • Tablets or suspension: 20 mg three times a day. The dose may be titrated up to a maximum of 80 mg three times a day, if required, based on symptoms and tolerability.
  • Injection: 10 mg as an intravenous bolus three times a day, for people who cannot take tablets. A 10 mg injection is predicted to give the same effect as a 20 mg oral dose.
  • Oral suspension: 10 mg/mL, made up by the pharmacist, and bioequivalent to the 20 mg tablet at a 20 mg dose. It must be discarded 60 days after mixing.

The label explains that short-term studies showed no extra gain in exercise ability above 20 mg, but the delay in clinical worsening seen with long-term use in Study A1481324 supports doses up to 80 mg three times a day. No dose change is needed for mild to moderate liver impairment or for kidney impairment, including severe; severe liver impairment has not been studied (sections 8.6 and 8.7).

Dosing in children

Body weightRecommended doseUpper limit on the label
20 kg or less10 mg three times a dayNot stated
20 to 45 kg20 mg three times a dayNot stated
45 kg and over20 mg three times a day40 mg three times a day, if required

Source: REVATIO label section 2.2. The label states that a maximum dose in children has not been identified, and the 40 mg limit for children over 45 kg is based on adult experience. The oral suspension (10 mg/mL) comes with a 2 mL dosing syringe marked at 1 mL and 2 mL, so a 10 mg dose is 1 mL.

What SUPER-1 found

SUPER-1 studied 277 adults with PAH, given placebo or sildenafil 20, 40 or 80 mg three times a day for 12 weeks (the label's arms total 70, 69, 67 and 71; the published paper reports 278 randomised). Their mean age was 49, 75% were women, and the mean starting walk distance was 343 metres. Background treatments such as anticoagulants, diuretics and oxygen were allowed, but prostacyclin drugs and endothelin receptor antagonists were not.

Dose (three times a day)Placebo-corrected gain in 6-minute walk distanceAs a percentage
20 mg45 m+13.0%
40 mg46 m+13.3%
80 mg50 m+14.7%
Bar chart of the placebo-corrected increase in 6-minute walk distance after 12 weeks in SUPER-1: 45 metres with sildenafil 20 mg three times a day, 46 metres with 40 mg and 50 metres with 80 mg. The dose groups did not differ from each other.
Figure 1. Placebo-corrected gain in 6-minute walk distance by dose in SUPER-1. Source: Galie 2005 and REVATIO label section 14.

All three results were statistically significant against placebo (P<0.001), and the label notes the improvement was apparent by week 4 and held at weeks 8 and 12. All doses lowered pulmonary artery pressure and improved WHO functional class. Clinical worsening over the 12 weeks did not differ significantly from placebo. Among 222 patients who completed a year of sildenafil alone, the walk distance had improved by 51 metres from baseline (Galiè 2005).

The label's reading is that SUPER-1 showed no additional clinical benefit from doses higher than 20 mg three times a day for walking distance. That is why 20 mg three times a day is the starting and usual dose.

Why higher doses are still allowed

Study A1481324 was run after a dose-related imbalance in deaths was seen in the long-term children's study. It randomised 385 adults with PAH, most new to PAH treatment, to 5, 20 or 80 mg three times a day. The 5 mg dose is not approved; it served as a low-dose comparison.

Outcome5 mg (n = 129)20 mg (n = 128)80 mg (n = 128)
Deaths34 (26%)25 (20%)19 (15%)
Survival at 3 years (Kaplan-Meier)66%79%85%
Patients with clinical worsening523628
Hazard ratio for worsening vs 5 mg (99.7% CI)Reference0.63 (0.33 to 1.21)0.44 (0.22 to 0.89)
Bar chart of 3-year Kaplan-Meier survival in Study A1481324: 66% with sildenafil 5 mg three times a day (not an approved dose), 79% with 20 mg and 85% with 80 mg. Hazard ratios against 5 mg were 0.68 for 20 mg and 0.51 for 80 mg, and both 99.7% confidence intervals included 1.
Figure 2. Three-year survival by sildenafil dose in adults with PAH, Study A1481324. Source: REVATIO label section 14.

Source: REVATIO label section 14, Tables 6 and 7. The study's main aim was to rule out a doubling of deaths at 80 mg compared with 5 mg, and it met that aim (hazard ratio 0.51, 99.7% CI 0.22 to 1.21). For survival, the confidence intervals for both 20 mg and 80 mg against 5 mg included 1, so the survival differences on their own were not statistically conclusive. For clinical worsening, 80 mg was better than 5 mg. Compared directly with 20 mg, 80 mg gave a hazard ratio of 0.72 (99.7% CI 0.34 to 1.52, p = 0.195), which was not significant.

Adding sildenafil to other PAH medicines

Two trials on the label tested sildenafil on top of another PAH drug, with different results:

  • With intravenous epoprostenol (PACES-1, 267 patients): sildenafil, titrated from 20 to 80 mg three times a day, added 26 metres to the 6-minute walk at week 16 compared with placebo (95% CI 10.8 to 41.2). Clinical worsening occurred in 8 of 134 patients on sildenafil against 23 of 131 on placebo, and 36% vs 14% improved by at least one functional class. Swelling (oedema) was more common: 25% vs 13%.
  • With bosentan (Study A1481243, 103 patients): adding sildenafil 20 mg three times a day made no significant difference to the 6-minute walk compared with bosentan alone.

Bosentan matters for another reason: it speeds up the breakdown of sildenafil. The label says the sildenafil dose may need to go up when a moderate to strong CYP3A inducer such as bosentan is started, and should go back to 20 mg three times a day when it is stopped.

Side effects at 20 mg

The label's Table 1 lists adverse reactions reported by at least 10% of patients in any sildenafil group in SUPER-1 and more often than on placebo:

Adverse reactionPlacebo (n = 70)20 mg (n = 69)40 mg (n = 67)80 mg (n = 71)
Headache39%46%42%49%
Dyspepsia (indigestion)7%13%8%13%
Back pain11%13%13%9%
Flushing4%10%9%16%
Diarrhoea6%9%12%10%
Pain in limb6%7%15%9%
Myalgia (muscle pain)4%7%6%14%
Grouped bar chart of adverse reactions in SUPER-1 for placebo, sildenafil 20 mg and 80 mg three times a day: headache 39%, 46%, 49%; dyspepsia 7%, 13%, 13%; back pain 11%, 13%, 9%; flushing 4%, 10%, 16%; diarrhoea 6%, 9%, 10%; muscle pain 4%, 7%, 14%.
Figure 3. Most common adverse reactions in SUPER-1, placebo vs sildenafil 20 mg and 80 mg three times a day. Source: REVATIO label Table 1.

The label describes these reactions as generally transient and mild to moderate. Discontinuation due to side effects was 3% at 20 and 40 mg, 8% at 80 mg and 3% on placebo. In the children's trial (STARTS-1, 234 patients), increased erections were reported in 9% of children treated with sildenafil, and no other new adverse reactions were found. The patient leaflet states that the most common side effect of REVATIO in children is an erection that lasts for more than 4 hours (priapism).

Nosebleeds and bleeding

Nosebleeds (epistaxis) get their own warning. In patients whose PAH was linked to connective tissue disease, 13% had nosebleeds on sildenafil. In idiopathic PAH the rate was 3% against 2% on placebo. Nosebleeds were also more frequent in people also taking an oral vitamin K antagonist such as warfarin: 9% vs 2% without one. The label states that the safety of sildenafil is unknown in people with bleeding disorders or active peptic ulcers (section 5.3).

The children's death imbalance: what the label says now

In the children's studies, STARTS-1 and its long-term extension STARTS-2, more deaths occurred in higher dose groups: 5 of 55 (9.1%) on the low dose, 10 of 74 (13.5%) on the medium dose and 22 of 100 (22%) on the high dose. The deaths were related to progression of PAH.

The current label states that this pattern was not confirmed in the adult study designed to test it (A1481324), where higher doses did better. Given that result and the expected similarity of the disease in children and adults, the label concludes that a causal link between dose and death in children is unlikely, and supports dosing up to 40 mg three times a day in children over 45 kg (section 8.4). Children's doses are set by weight and by a specialist. In STARTS-1 the high-dose group gave children over 45 kg 80 mg per dose (label Table 5); the current label's limit for that weight is 40 mg three times a day.

Who must not take sildenafil 20 mg

The label lists three contraindications (section 4):

  • Nitrates in any form, taken regularly or now and then (for example nitroglycerin for chest pain), because of the risk of a dangerous fall in blood pressure.
  • Riociguat, another PAH medicine, because sildenafil may strengthen its blood pressure lowering effect.
  • Known hypersensitivity to sildenafil or any ingredient, including reported anaphylaxis.

The Viagra label also warns against "poppers" (amyl or butyl nitrite) for the same reason as nitrates.

Warnings worth knowing

  • Low blood pressure: prescribers are told to consider whether people on blood pressure medicines, with resting blood pressure below 90/50, fluid loss, severe left ventricular outflow obstruction or autonomic dysfunction could be harmed, and to monitor blood pressure when other blood pressure lowering drugs are used (5.1). The names and classes of common blood pressure medicines are in our blood pressure medication guide.
  • Pulmonary veno-occlusive disease (PVOD): use is not recommended, because lung vasodilators can significantly worsen it. Signs of fluid on the lungs should raise the possibility of PVOD (5.2).
  • Sudden vision loss: NAION, a cause of decreased vision including permanent loss, has been reported with PDE5 inhibitors used for ED. Seek immediate medical help for sudden loss of vision in one or both eyes. Use in retinitis pigmentosa is not recommended (5.4).
  • Sudden hearing loss: sometimes with ringing in the ears and dizziness; seek prompt medical help (5.5).
  • Priapism: use with caution in men with a deformed penis (angulation, cavernosal fibrosis or Peyronie's disease) or conditions that predispose to priapism (sickle cell anaemia, multiple myeloma or leukaemia). An erection lasting more than 4 hours needs immediate medical help. If priapism (a painful erection lasting more than 6 hours) is not treated immediately, penile tissue damage and permanent loss of potency could result (5.7).
  • Pulmonary hypertension from sickle cell disease: in a small trial stopped early, painful vaso-occlusive crises needing hospital care were more common on sildenafil than placebo. Effectiveness and safety in this group have not been established (5.8).

Interactions

Combined withWhat the REVATIO label says
NitratesContraindicated
RiociguatContraindicated
Strong CYP3A inhibitors (for example ketoconazole, itraconazole, ritonavir)Not recommended
Moderate to strong CYP3A inducers (for example bosentan)Lower sildenafil levels; dose may need to go up, and back to 20 mg three times a day when the inducer is stopped
Viagra or other PDE5 inhibitorsNot studied; patients are told not to take them together
Blood pressure medicinesMonitor blood pressure
AlcoholSildenafil 50 mg did not add to the blood pressure effect of alcohol in healthy volunteers with mean peak blood alcohol levels of 0.08%

Sources: REVATIO label sections 4, 5.1, 5.6, 7 and 12.3. The point about other PDE5 inhibitors is practical: someone on 20 mg three times a day for PAH should not add an ED tablet such as Viagra, Cialis or Levitra without their PAH specialist's agreement.

Pregnancy and breastfeeding

The label says that limited published data do not show a clear link between sildenafil and major birth defects, miscarriage or poor outcomes for mother or baby, and that untreated PAH in pregnancy carries risks of heart failure, stroke, preterm delivery and death of mother and baby. Animal studies showed no harm to the fetus at 32 and 65 times the recommended human dose in rats and rabbits. Sildenafil and its active metabolite have been found in breast milk in a case report, and there is not enough information to judge the risk to a breastfed baby (sections 8.1 and 8.2). Pregnancy with PAH needs specialist care.

How the body handles a 20 mg dose

The label reports these pharmacokinetic facts (section 12.3):

  • Peak blood level is reached 30 to 120 minutes after an oral dose (median 60 minutes) when fasted.
  • A high-fat meal delays the peak by about 60 minutes and lowers it by 29%.
  • Sildenafil and its active metabolite both have a terminal half-life of about 4 hours.
  • In people with PAH, average steady-state levels were 20 to 50% higher than in healthy volunteers.
  • Healthy people aged 65 or older had about 84% higher sildenafil levels than younger adults.

For how long a single ED dose of sildenafil keeps working, see our guide to how long sildenafil lasts.

Why 20 mg tablets come up in ED discussions

Because the 20 mg tablet contains the same drug as Viagra, people ask whether it can be used for ED. Here is what the sources support, and nothing more:

  • The 20 mg tablet is labelled for PAH only. Using it for ED is off-label, which the FDA describes as "unapproved use of an approved drug". The FDA says healthcare providers generally may prescribe a drug for an unapproved use when they judge it medically appropriate for their patient.
  • The ED label doses are 25, 50 and 100 mg, taken as needed, no more than once a day, with 50 mg the usual start. A 20 mg tablet does not match any of those steps, so any ED regimen built from 20 mg tablets is a prescriber's choice that the Viagra label does not describe.
  • The ED label sets lower starting doses (25 mg) for people over 65, people with liver cirrhosis or severe kidney impairment, and people on strong CYP3A4 inhibitors or erythromycin, a 25 mg start for men already stable on an alpha blocker, and a 25 mg maximum in 48 hours with ritonavir. Those rules apply to the drug, whatever the tablet strength.
  • The REVATIO patient leaflet says: "Do not use REVATIO for a condition for which it was not prescribed."

The safe route is to discuss ED with a doctor, who can decide the dose and strength. For ED dosing, success rates and side effects, see our guide to what sildenafil is and how well it works, and for nitrates, alpha blockers and dose limits, our guide to taking sildenafil safely. Doses above 100 mg are covered in sildenafil 150 mg and 200 mg.

What a 20 mg tablet costs US pharmacies

The National Average Drug Acquisition Cost (NADAC), published by CMS, records what US retail pharmacies pay to buy drugs. It is not the price a patient pays: pharmacies add dispensing fees and margin, and insurance and discount programmes change what you pay at the counter. In the NADAC file with an as of date of 14 October 2026, generic sildenafil prices per tablet were:

Generic sildenafil tabletNADAC per tabletPer mg of sildenafilNDC rows that week
20 mg$0.05105$0.0025523
25 mg$0.12199$0.0048819
50 mg$0.10675$0.0021429
100 mg$0.13192$0.0013233
Bar chart of NADAC per tablet for generic sildenafil as of 14 October 2026: 20 mg $0.05105, 25 mg $0.12199, 50 mg $0.10675, 100 mg $0.13192.
Figure 4. What US pharmacies pay per generic sildenafil tablet, by strength. Source: CMS NADAC, 14 October 2026.

Two points follow from these figures. First, a month of the usual PAH dose (90 tablets of 20 mg) cost pharmacies about $4.59 at NADAC. Second, the 20 mg tablet is the cheapest per tablet but not per milligram: five 20 mg tablets ($0.26) cost pharmacies about twice as much as one 100 mg tablet ($0.13). Brand Viagra 100 mg was $83.71647 per tablet the same week. The 20 mg generic price also fell from $0.05461 in the first file of 2026 (7 January) to $0.05105. For brand vs generic gaps across more medicines, see our NADAC brand vs generic price comparison.

Common mistakes to avoid

  • Treating PAH as a self-care condition. PAH is confirmed by catheter measurements of lung artery pressure and needs specialist follow-up. A tablet bought to "help breathing" can hide a serious cause of breathlessness.
  • Taking an ED tablet on top of a PAH prescription. Both labels say not to combine sildenafil products or other PDE5 inhibitors.
  • Missing the nitrate rule. Nitrates in any form, including sprays and patches for angina, are contraindicated.
  • Changing the PAH dose without advice. The patient leaflet says not to change the dose or stop without talking to your healthcare provider.
  • Ignoring sudden vision or hearing changes. Both need urgent medical attention.

Where SafeRxPills fits

SafeRxPills lists two sildenafil 20 mg brands made in India: Assurans 20 mg (Cipla) and Cardiax 20 mg (Healing Pharma). They are not the US-approved REVATIO or its FDA-approved generics. Sildenafil is a prescription medicine, PAH should be managed by a specialist, and any order should follow your own doctor's prescription and the rules of your country. For checks to make before buying sildenafil online, see our guide to checking a sildenafil seller; country rules are in buying sildenafil online in the US, UK, Canada and Australia.

Sources

  • REVATIO (sildenafil) tablets, injection and oral suspension, US prescribing information and patient information. Viatris Specialty LLC, DailyMed setid 3bb9363e-b28d-4019-8aae-539233dca214, effective December 2024 (revised December 2024). Sections 1, 2, 3, 4, 5, 6.1, 7, 8, 12 and 14.
  • VIAGRA (sildenafil citrate) tablets, US prescribing information and patient information. Viatris Specialty LLC, DailyMed setid d905dc8d-917f-4ea3-a4ee-a1ecf6967d4e, revised 11/2023. Sections 1, 2, 3 and 4.
  • Galiè N et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005;353(20):2148-57. PMID 16291984 (SUPER-1).
  • US Food and Drug Administration. Understanding Unapproved Use of Approved Drugs "Off Label" (content current as of 5 February 2018). FDA
  • Centers for Medicare & Medicaid Services. National Average Drug Acquisition Cost (NADAC) 2026, as of date 14 October 2026 and 7 January 2026. data.medicaid.gov

This article is for information only and is not medical advice. Sildenafil is a prescription medicine in most countries. Pulmonary arterial hypertension must be diagnosed and treated by a specialist. Talk to a doctor or pharmacist before starting, stopping or changing any treatment.

?Frequently Asked Questions

What is sildenafil 20 mg used for?

Sildenafil 20 mg tablets are approved to treat pulmonary arterial hypertension (PAH, WHO Group I), high blood pressure in the arteries of the lungs. The US REVATIO label covers adults, to improve exercise ability and delay clinical worsening, and children aged 1 to 17. It is not labelled for erectile dysfunction.

Is sildenafil 20 mg the same as Viagra?

It is the same active ingredient, sildenafil citrate, but a different product. REVATIO and its generics come as 20 mg tablets taken three times a day for PAH. Viagra comes as 25, 50 and 100 mg tablets taken as needed, no more than once a day, for erectile dysfunction. Both labels say not to take the two together.

How often do you take sildenafil 20 mg for pulmonary hypertension?

The recommended adult dose is 20 mg three times a day. A doctor may raise it up to a maximum of 80 mg three times a day based on symptoms and tolerability. For people who cannot take tablets, the injection dose is 10 mg three times a day.

Does a higher dose than 20 mg work better for PAH?

For walking distance, no clear gain was seen: in SUPER-1, 20, 40 and 80 mg three times a day improved the 6-minute walk by 45, 46 and 50 metres over placebo, and the doses did not differ. In a later study of 385 adults, 80 mg reduced clinical worsening compared with 5 mg (hazard ratio 0.44), which is why the label allows doses up to 80 mg three times a day.

What are the side effects of sildenafil 20 mg?

In SUPER-1 the most common adverse reactions on 20 mg three times a day were headache (46% vs 39% on placebo), dyspepsia (13% vs 7%), back pain (13% vs 11%), flushing (10% vs 4%), diarrhoea (9% vs 6%), and limb and muscle pain (7% each). Nosebleeds are also listed, especially in PAH linked to connective tissue disease (13%). Discontinuation due to side effects was 3% at 20 mg.

Can children take sildenafil 20 mg?

Yes, the current US label includes PAH in children aged 1 to 17. Children of 20 kg or less take 10 mg three times a day, and those over 20 kg take 20 mg three times a day, with up to 40 mg three times a day allowed above 45 kg. It has not been established under 1 year of age.

Who should not take sildenafil 20 mg?

It is contraindicated with nitrates in any form, with riociguat, and in people allergic to sildenafil. It is not recommended with pulmonary veno-occlusive disease, retinitis pigmentosa or strong CYP3A inhibitors such as ketoconazole, itraconazole or ritonavir, and should not be combined with Viagra or other PDE5 inhibitors.

Can sildenafil 20 mg tablets be used for erectile dysfunction?

The 20 mg tablet is labelled for PAH only, so using it for ED is off-label. The FDA says prescribers generally may prescribe an approved drug for an unapproved use when they judge it medically appropriate. The ED label doses are 25, 50 and 100 mg, so any ED plan using 20 mg tablets is for a doctor to decide, not something to work out yourself.

How much does a generic sildenafil 20 mg tablet cost?

In the CMS NADAC file dated 14 October 2026, US pharmacies paid a median $0.05105 per generic 20 mg tablet, about $4.59 for 90 tablets. NADAC is the pharmacy's purchase cost, not the price a patient pays, which adds dispensing fees and margin and depends on insurance or discounts.

How long does sildenafil 20 mg stay in the body?

Sildenafil and its active metabolite both have a terminal half-life of about 4 hours. After an oral dose, peak blood level comes 30 to 120 minutes later (median 60 minutes) when fasted; a high-fat meal delays the peak by about an hour and lowers it by 29%.

Is sildenafil 20 mg safe in pregnancy?

The label says limited published data do not show a clear link with major birth defects, miscarriage or poor outcomes, while untreated PAH in pregnancy carries serious risks to mother and baby, including heart failure, stroke and death. Pregnancy with PAH needs specialist care, and decisions about sildenafil should be made with that team.

L

Lokesh Maurya

Pharmacist, Content, B.Pharm, M.Pharm, Rajiv Gandhi University

Pharmacist writing on antiparasitic, ophthalmic and dermatological generics. Focuses on what the regulatory labelling and published evidence actually support.

Comments (0)

Leave a Comment

No comments yet. Be the first to share your thoughts!